Glycan-Based Near-infrared Fluorescent (NIRF) Imaging of Gastrointestinal Tumors: a Preclinical Proof-of-Concept In Vivo Study.
Aberrant glycosylation
Carbohydrates
Fluorescence-guided surgery
Lewis glycans
Monoclonal antibody
Journal
Molecular imaging and biology
ISSN: 1860-2002
Titre abrégé: Mol Imaging Biol
Pays: United States
ID NLM: 101125610
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
10
04
2020
accepted:
21
07
2020
revised:
07
07
2020
pubmed:
12
8
2020
medline:
6
8
2021
entrez:
12
8
2020
Statut:
ppublish
Résumé
Aberrantly expressed glycans in cancer are of particular interest for tumor targeting. This proof-of-concept in vivo study aims to validate the use of aberrant Lewis glycans as target for antibody-based, real-time imaging of gastrointestinal cancers. Immunohistochemical (IHC) staining with monoclonal antibody FG88.2, targeting Lewis IHC analysis showed strong FG88.2 staining on colonic, gastric, and pancreatic tumors, while staining on their normal tissue counterparts was limited. Next, human cancer cell lines HT-29 (colon) and BxPC-3 and PANC-1 (both pancreatic) were identified as respectively high, moderate, and low Lewis Using a novel chimeric Lewis
Identifiants
pubmed: 32780212
doi: 10.1007/s11307-020-01522-8
pii: 10.1007/s11307-020-01522-8
pmc: PMC7666282
doi:
Substances chimiques
Antibodies, Monoclonal
0
Benzenesulfonates
0
IRDye 800CW
0
Indoles
0
Polysaccharides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1511-1522Subventions
Organisme : Medical Research Council
ID : MR/M015564/1
Pays : United Kingdom
Références
Verbeek FP, van der Vorst JR, Schaafsma BE et al (2012) Image-guided hepatopancreatobiliary surgery using near-infrared fluorescent light. J Hepatobiliary Pancreat Sci 19:626–637
doi: 10.1007/s00534-012-0534-6
Hernot S, van Manen L, Debie P, Mieog JSD, Vahrmeijer AL (2019) Latest developments in molecular tracers for fluorescence image-guided cancer surgery. Lancet Oncol 20:e354–e367
doi: 10.1016/S1470-2045(19)30317-1
Boonstra MC, Tolner B, Schaafsma BE, Boogerd LSF, Prevoo HAJM, Bhavsar G, Kuppen PJK, Sier CFM, Bonsing BA, Frangioni JV, van de Velde CJH, Chester KA, Vahrmeijer AL (2015) Preclinical evaluation of a novel CEA-targeting near-infrared fluorescent tracer delineating colorectal and pancreatic tumors. Int J Cancer 137:1910–1920
doi: 10.1002/ijc.29571
van Driel PBAA, Boonstra MC, Prevoo HAJM, van de Giessen M, Snoeks TJA, Tummers QRJG, Keereweer S, Cordfunke RA, Fish A, van Eendenburg JDH, Lelieveldt BPF, Dijkstra J, van de Velde CJH, Kuppen PJK, Vahrmeijer AL, Löwik CWGM, Sier CFM (2016) EpCAM as multi-tumour target for near-infrared fluorescence guided surgery. BMC Cancer 16:884
doi: 10.1186/s12885-016-2932-7
Boogerd LSF, Boonstra MC, Prevoo H et al (2019) Fluorescence-guided tumor detection with a novel anti-EpCAM targeted antibody fragment: preclinical validation. Surg Oncol 28:1–8
doi: 10.1016/j.suronc.2018.10.004
Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, van Dongen GA, Schröder CP, Lub-de Hooge MN, de Vries EG (2010) Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87:586–592
doi: 10.1038/clpt.2010.12
Handgraaf HJM, Boonstra MC, Prevoo H et al (2017) Real-time near-infrared fluorescence imaging using cRGD-ZW800-1 for intraoperative visualization of multiple cancer types. Oncotarget 8:21054–21066
doi: 10.18632/oncotarget.15486
Boogerd LSF, Hoogstins CES, Schaap DP, Kusters M, Handgraaf HJM, van der Valk MJM, Hilling DE, Holman FA, Peeters KCMJ, Mieog JSD, van de Velde CJH, Farina-Sarasqueta A, van Lijnschoten I, Framery B, Pèlegrin A, Gutowski M, Nienhuijs SW, de Hingh IHJT, Nieuwenhuijzen GAP, Rutten HJT, Cailler F, Burggraaf J, Vahrmeijer AL (2018) Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study. Lancet Gastroenterol Hepatol 3:181–191
doi: 10.1016/S2468-1253(17)30395-3
Rosenthal EL, Warram JM, de Boer E, Chung TK, Korb ML, Brandwein-Gensler M, Strong TV, Schmalbach CE, Morlandt AB, Agarwal G, Hartman YE, Carroll WR, Richman JS, Clemons LK, Nabell LM, Zinn KR (2015) Safety and tumor specificity of cetuximab-IRDye800 for surgical navigation in head and neck cancer. Clin Cancer Res 21:3658–3666
doi: 10.1158/1078-0432.CCR-14-3284
Lamberts LE, Koch M, de Jong JS, Adams ALL, Glatz J, Kranendonk MEG, Terwisscha van Scheltinga AGT, Jansen L, de Vries J, Lub-de Hooge MN, Schröder CP, Jorritsma-Smit A, Linssen MD, de Boer E, van der Vegt B, Nagengast WB, Elias SG, Oliveira S, Witkamp AJ, Mali WPTM, van der Wall E, van Diest PJ, de Vries EGE, Ntziachristos V, van Dam GM (2017) Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study. Clin Cancer Res 23:2730–2741
doi: 10.1158/1078-0432.CCR-16-0437
Pinho SS, Reis CA (2015) Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer 15:540–555
doi: 10.1038/nrc3982
Munkley J, Elliott DJ (2016) Hallmarks of glycosylation in cancer. Oncotarget 7:35478–35489
doi: 10.18632/oncotarget.8155
Pinho S, Marcos NT, Ferreira B, Carvalho AS, Oliveira MJ, Santos-Silva F, Harduin-Lepers A, Reis CA (2007) Biological significance of cancer-associated sialyl-Tn antigen: modulation of malignant phenotype in gastric carcinoma cells. Cancer Lett 249:157–170
doi: 10.1016/j.canlet.2006.08.010
Munkley J (2016) The role of Sialyl-Tn in Cancer. Int J Mol Sci 17:275
doi: 10.3390/ijms17030275
Blanas A, Sahasrabudhe NM, Rodríguez E, van Kooyk Y, van Vliet SJ (2018) Fucosylated antigens in cancer: an alliance toward tumor progression, metastasis, and resistance to chemotherapy. Frontiers in oncology, 8, 39
Fuster MM, Esko JD (2005) The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 5:526–542
doi: 10.1038/nrc1649
Rabu C, McIntosh R, Jurasova Z, Durrant L (2012) Glycans as targets for therapeutic antitumor antibodies. Future Oncol 8:943–960
doi: 10.2217/fon.12.88
Chua JX, Vankemmelbeke M, McIntosh RS et al (2015) Monoclonal antibodies targeting LecLex-related glycans with potent antitumor activity. Clin Cancer Res 21:2963–2974
doi: 10.1158/1078-0432.CCR-14-3030
Mahler Convenor M, Berard M, Feinstein R et al (2014) FELASA recommendations for the health monitoring of mouse, rat, hamster, guinea pig and rabbit colonies in breeding and experimental units. Lab Anim 48:178–192
doi: 10.1177/0023677213516312
Rueden CT, Schindelin J, Hiner MC, DeZonia BE, Walter AE, Arena ET, Eliceiri KW (2017) ImageJ2: ImageJ for the next generation of scientific image data. BMC Bioinformatics 18:529
doi: 10.1186/s12859-017-1934-z
van Manen L, Handgraaf HJM, Diana M, Dijkstra J, Ishizawa T, Vahrmeijer AL, Mieog JSD (2018) A practical guide for the use of indocyanine green and methylene blue in fluorescence-guided abdominal surgery. J Surg Oncol 118:283–300
doi: 10.1002/jso.25105
Gersten KM, Natsuka S, Trinchera M, Petryniak B, Kelly RJ, Hiraiwa N, Jenkins NA, Gilbert DJ, Copeland NG, Lowe JB (1995) Molecular cloning, expression, chromosomal assignment, and tissue-specific expression of a murine alpha-(1,3)-fucosyltransferase locus corresponding to the human ELAM-1 ligand fucosyl transferase. J Biol Chem 270:25047–25056
doi: 10.1074/jbc.270.42.25047
Tauchi K, Kakudo K, Machimura T, Makuuchi H, Mitomi T (1991) Immunohistochemical studies of blood group-related antigens in human superficial esophageal carcinomas. Cancer 67:3042–3050
doi: 10.1002/1097-0142(19910615)67:12<3042::AID-CNCR2820671219>3.0.CO;2-L
Pour PM, Tempero MM, Takasaki H et al (1988) Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in pancreatic cancer cells in comparison with the patient’s blood group type. Cancer Res 48:5422–5426
pubmed: 3166398
Itzkowitz SH, Yuan M, Ferrell LD, Ratcliffe RM, Chung YS, Satake K, Umeyama K, Jones RT, Kim YS (1987) Cancer-associated alterations of blood group antigen expression in the human pancreas2. J Natl Cancer Inst 79:425–434
pubmed: 2442445
Itzkowitz SH, Yuan M, Fukushi Y, Lee H, Shi ZR, Zurawski V Jr, Hakomori S, Kim YS (1988) Immunohistochemical comparison of Lea, monosialosyl Lea (CA 19-9), and disialosyl Lea antigens in human colorectal and pancreatic tissues. Cancer Res 48:3834–3842
pubmed: 3288336
Schoentag R, Primus FJ, Kuhns W (1987) ABH and Lewis blood group expression in colorectal carcinoma. Cancer Res 47:1695–1700
pubmed: 3815366
Sakamoto S, Watanabe T, Tokumaru T et al (1989) Expression of Lewisa, Lewisb, Lewisx, Lewisy, siayl-Lewisa, and sialyl-Lewisx blood group antigens in human gastric carcinoma and in normal gastric tissue. Cancer Res 49:745–752
pubmed: 2910493
Serpa J, Mesquita P, Mendes N, Oliveira C, Almeida R, Santos-Silva F, Reis CA, LePendu J, David L (2006) Expression of Lea in gastric cancer cell lines depends on FUT3 expression regulated by promoter methylation. Cancer Lett 242:191–197
doi: 10.1016/j.canlet.2005.11.009
Itzkowitz SH, Yuan M, Ferrell LD, Palekar A, Kim YS (1986) Cancer-associated alterations of blood group antigen expression in human colorectal polyps. Cancer Res 46:5976–5984
pubmed: 2428489
Blaszczyk M, Pak KY, Herlyn M, Sears HF, Steplewski Z (1985) Characterization of Lewis antigens in normal colon and gastrointestinal adenocarcinomas. Proc Natl Acad Sci U S A 82:3552–3556
doi: 10.1073/pnas.82.11.3552
Sawada R, Sun SM, Wu X, Hong F, Ragupathi G, Livingston PO, Scholz WW (2011) Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity. Clin Cancer Res 17:1024–1032
doi: 10.1158/1078-0432.CCR-10-2640
Houghton JL, Zeglis BM, Abdel-Atti D, Aggeler R, Sawada R, Agnew BJ, Scholz WW, Lewis JS (2015) Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer. Proc Natl Acad Sci U S A 112:15850–15855
doi: 10.1073/pnas.1506542112
Houghton JL, Abdel-Atti DA, Sawada R, Scholz WW, Lewis JS (2015) Abstract B25: development of 5B1, an anti-CA19.9 monoclonal antibody, as a near-infrared fluorescent probe for intraoperative imaging of pancreatic cancer. Cancer Res 75:B25
Ballehaninna UK, Chamberlain RS (2011) Serum CA 19-9 as a biomarker for pancreatic cancer—a comprehensive review. Indian journal of surgical oncology 2:88–100
doi: 10.1007/s13193-011-0042-1
Schwenk J, Makovitzky J (1989) Tissue expression of the cancer-associated antigens CA 19-9 and CA-50 in chronic pancreatitis and pancreatic carcinoma. Int J Pancreatol 5:85–98
pubmed: 2746048